Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19-CAR γδT-cells in B-cell Malignancies
NCT02656147Phase 1Unknown
- Sponsor
- Beijing DOING Biomedical Technology
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19-CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (3 cohorts), sponsored by Beijing DOING Biomedical Technology. Primary endpoint: Adverse events of each patient at 3 years. Status: unknown.
02
Drugs
CD19-CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02656147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656147.